Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, The Edge Partner on Software Solutions for Biopharma

NEW YORK (GenomeWeb News) – Accelrys today announced a partnership with The Edge Software Consultancy to offer new assay, study management, and analysis software solutions to the biopharmaceutical industry.

The software products to be developed by the companies are directed at improving R&D efficiency and productivity of biopharmaceutical firms performing early-stage screening through ADME, DMPK, pharmacology, and in vivo experiments.

Under the agreement, Accelrys will market and sell software products developed in collaboration with The Edge under three product names: Accelrys BioRails DM Suite, for general assay and study data management; Accelrys BioRails PTO, to track projects and optimize experiments in BioRails; and Accelrys Morphit, for the capture, analysis, and modeling of biological study data.

Financial and other terms of the deal were not disclosed.

The partners will also work to integrate Morphit and BioRail components with Accelrys' Symyx Notebook "to deliver flexible templates for structured data management and scientific analysis," Accelrys said.

The Edge is based in Guildford, Surrey, UK and provides professional enterprise and desktop solutions and services.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.